Menu
Recruiting NCT07148063

Inflammatory Biomarkers as Predictors of PONV Following Pediatric Orchiopexy

— Observational Pediatric Anesthesia Postoperative Nausea and Vomiting (PONV) Inflammatory Biomarkers

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Measurement of Preoperative Inflammatory Biomarkers.
Who it may be relevant to
Registry conditions: Pediatric Anesthesia, Postoperative Nausea and Vomiting (PONV), Inflammatory Biomarkers. Basic parameters: 1 year — 8 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Association of Preoperative Inflammatory Biomarkers With Postoperative Nausea and Vomiting in Children Undergoing Orchiopexy

Overview

Orchiopexy is a common surgical procedure for the treatment of cryptorchidism in the pediatric population, with a high incidence of postoperative nausea and vomiting (PONV). Recent evidence suggests that systemic inflammation may contribute to PONV pathogenesis, and preoperative inflammatory biomarkers such as NLR, PLR, SII, MLR, and SIRI could serve as predictive indicators. This prospective observational study aims to evaluate the relationship between these biomarkers and PONV incidence in children undergoing orchiopexy.

Interventions

  • Other Measurement of Preoperative Inflammatory Biomarkers
    Blood samples will be collected preoperatively to measure inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index, monocyte-to-lymphocyte ratio (MLR), and systemic inflammation response index. These values will be analysed in relation to the incidence of postoperative nausea and vomiting within the first 6 hours after pediatric orchiopexy. No experimental drug or device will be administered as part of the stu

Primary outcome measures

  • Incidence of Postoperative Nausea and Vomiting (PONV) [Time frame: Within 6 hours postoperatively]
Secondary outcome measures (1)
  • Need for Antiemetic Treatment [Time frame: Within 6 hours postoperatively]

Eligibility criteria

Inclusion criteria

  • Patients aged between 1 and 8 years
  • Patients with ASA physical status I-II
  • Patients scheduled for elective orchiopexy
  • Obtained written informed consent from parents/guardians

Exclusion criteria

  • Patients younger than 1 year or older than 8 years
  • Patients with ASA physical status III or higher
  • Presence of acute infection signs
  • History of previous nausea or vomiting

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Turkey (Türkiye) · 1 center
  • Ankara Etlik City Hospital — Altındağ

Identifiers

NCT: NCT07148063 · AEŞH-EK-2025-205

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗